FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2318373338> ?p ?o ?g. }

• W2318373338 endingPage "S11.004" @default.
• W2318373338 startingPage "S11.004" @default.
• W2318373338 abstract "Objective: To report the BG-12 effects on magnetization transfer ratio (MTR) in the Phase 3 DEFINE study. Background Brain MTR measurements are considered to be sensitive to changes in myelin and axonal content, with increases reflecting higher concentrations of myelin and axons. DEFINE examined MTR changes with BG-12 treatment in the magnetic resonance imaging cohort. Design/Methods: DEFINE was a randomized, double-blind, placebo-controlled study evaluating BG-12 over 2 years in relapsing-remitting multiple sclerosis (RRMS). Patients aged 18-55 years with RRMS (McDonald criteria) and an Expanded Disability Status Scale score of 0.0-5.0 were randomized 1:1:1 to placebo or BG-12 240 mg twice (BID) or three times daily (TID). MTR was analyzed in whole brain (WB) and normal-appearing brain tissue (NABT) at baseline, 1, and 2 years. Results: MTR analysis included 392 patients. In WB, mean percentage change from baseline at 2 years in median MTR was -0.386% in the placebo group versus 0.129% ( P =0.0027) and 0.096% ( P =0.0051) with BID and TID, respectively, indicating significant increases relative to placebo. In NABT, mean percentage change from baseline at 2 years in median MTR was -0.392% with placebo versus 0.190% ( P =0.0006) and 0.115% ( P =0.0029) with BG-12 BID and TID, respectively. The post hoc analysis performed on patients with no new/enlarging T2 lesions (N=147) demonstrated decreased WB MTR with placebo (mean percentage change, -0.379%), but increased WB MTR with the BG-12 BID (mean percentage change, 0.286%; P =0.0293) and TID (mean percentage change, 0.170%; P =0.0538) groups at 2 years. Likewise, MTR in NABT decreased in the placebo group (mean percentage change, -0.312%) and increased in the BID (mean percentage change, 0.314%; P =0.0285) and TID (mean percentage change, 0.171%; P =0.0644) groups at 2 years. Conclusions: DEFINE MTR results demonstrate increased brain MTR in BG-12-treated patients, potentially reflecting protective effects leading to increased myelin and axonal content. Supported by: Biogen Idec Inc. Disclosure: Dr. Arnold has received personal compensation for activities with Bayer Healthcare, Biogen Idec, Genentech, Inc., NeuroRx Research, Roche Diagnostics Corporation, Schering, Serono, Inc., and Teva Neuroscience. Dr. Arnold Dr. Arnold has received research support from Bayer Healthcare, Biogen Idec, Genentech, Inc., NeuroRx Research, Roche Diagnostics Corporation, Schering, Serono, Inc., and Teva Neuroscience. Dr. Gold has received personal compensation for activities with Bayer Pharmaceuticals Corporation, Biogen Idec, Merck Serono, Teva Neuroscience. Dr. Gold has received personal compensation in an editorial capacity for Therapeutic Advances in Neurological Disorders. Dr. Gold has received (royalty or license fee or contractual rights) payments from Biogen Idec. Dr. Gold has received research support from Bayer Pharmaceuticals Corporation, Biogen Idec, Merck Serono, Novartis and Teva Neuroscience. Dr. Kappos has received research support from Acorda Therapeutics, Actelion, Allozyne, BaroFold, Inc., Bayer Pharmaceuticals Corporation, Bayhill Therapeutics, Biogen Idec, Boehringer Ingelheim Pharmaceuticals, Inc, Elan Corporation, Genmab, GlaxoSmithKline, Inc., Glenmark Pharma, Merck Serono, MediciNova, Novartis, Sanofi-Aventis Pharmaceuticals, Santhera Pharmaceuticals, Shire, Roche Diagnostics, Teva Neuroscience, UCB Pharma, Pfizer Inc, Swiss MS Society, Swiss National Research Foundation, European Union, Gianni Rubatto Foundation, Novartis and Roche Research Foundations. Dr. Bar-Or has received personal compensation for activities with Aventis Pharmaceuticals, Bayhill Therapeutics, Biogen Idec, Berlex Laboratories, Eli Lilly & Company, Genentech, Inc., GlaxoSmithKline, Ono Pharmaceutical, Diogenix, Roche Diagnostics Corporation, Merck Serono, Novartis, Teva Neuroscience. Dr. Giovannoni has received personal compensation for activities with Bayer-Pharmaceuticals Corporation, Biogen Idec, Five Prime Therapeutics, Inc, Genzyme Corporation, Ironwood Pharmaceuticals, Merck Serono, Novartis, Teva Neuroscience, Sanofi-Aventis Pharmaceuticals and Vertex Pharmaceuticals as a speaker, consultant and/or serving on data monitoring boards. Dr. Selmaj has received personal compensation for activities with Genzyme, Ono, and Biogen Idec. Ms. Yang has received personal compensation for activities with Biogen Idec as an employee. Dr. Stephan has received personal compensation for activities with Biogen Idec as an employee. Dr. Stephan has received research support from Biogen Idec. Dr. Dawson has received personal compensation for activities with Biogen Idec Inc. as an employee." @default.
• W2318373338 created "2016-06-24" @default.
• W2318373338 creator A5005022111 @default.
• W2318373338 creator A5010857296 @default.
• W2318373338 creator A5015754502 @default.
• W2318373338 creator A5021238426 @default.
• W2318373338 creator A5034380106 @default.
• W2318373338 creator A5073654164 @default.
• W2318373338 creator A5075052252 @default.
• W2318373338 creator A5076296435 @default.
• W2318373338 creator A5077310868 @default.
• W2318373338 date "2012-04-22" @default.
• W2318373338 modified "2023-09-26" @default.
• W2318373338 title "Effects of BG-12 on Magnetization Transfer Ratio in Whole Brain and Normal-Appearing Brain Tissue: Findings from the DEFINE Study (S11.004)" @default.
• W2318373338 doi "https://doi.org/10.1212/wnl.78.1_meetingabstracts.s11.004" @default.
• W2318373338 hasPublicationYear "2012" @default.
• W2318373338 type Work @default.
• W2318373338 sameAs 2318373338 @default.
• W2318373338 citedByCount "2" @default.
• W2318373338 countsByYear W23183733382013 @default.
• W2318373338 countsByYear W23183733382015 @default.
• W2318373338 crossrefType "journal-article" @default.
• W2318373338 hasAuthorship W2318373338A5005022111 @default.
• W2318373338 hasAuthorship W2318373338A5010857296 @default.
• W2318373338 hasAuthorship W2318373338A5015754502 @default.
• W2318373338 hasAuthorship W2318373338A5021238426 @default.
• W2318373338 hasAuthorship W2318373338A5034380106 @default.
• W2318373338 hasAuthorship W2318373338A5073654164 @default.
• W2318373338 hasAuthorship W2318373338A5075052252 @default.
• W2318373338 hasAuthorship W2318373338A5076296435 @default.
• W2318373338 hasAuthorship W2318373338A5077310868 @default.
• W2318373338 hasConcept C118552586 @default.
• W2318373338 hasConcept C126322002 @default.
• W2318373338 hasConcept C126838900 @default.
• W2318373338 hasConcept C142724271 @default.
• W2318373338 hasConcept C143409427 @default.
• W2318373338 hasConcept C204787440 @default.
• W2318373338 hasConcept C27081682 @default.
• W2318373338 hasConcept C2780640218 @default.
• W2318373338 hasConcept C27826641 @default.
• W2318373338 hasConcept C2989005 @default.
• W2318373338 hasConcept C67761136 @default.
• W2318373338 hasConcept C71924100 @default.
• W2318373338 hasConcept C90924648 @default.
• W2318373338 hasConceptScore W2318373338C118552586 @default.
• W2318373338 hasConceptScore W2318373338C126322002 @default.
• W2318373338 hasConceptScore W2318373338C126838900 @default.
• W2318373338 hasConceptScore W2318373338C142724271 @default.
• W2318373338 hasConceptScore W2318373338C143409427 @default.
• W2318373338 hasConceptScore W2318373338C204787440 @default.
• W2318373338 hasConceptScore W2318373338C27081682 @default.
• W2318373338 hasConceptScore W2318373338C2780640218 @default.
• W2318373338 hasConceptScore W2318373338C27826641 @default.
• W2318373338 hasConceptScore W2318373338C2989005 @default.
• W2318373338 hasConceptScore W2318373338C67761136 @default.
• W2318373338 hasConceptScore W2318373338C71924100 @default.
• W2318373338 hasConceptScore W2318373338C90924648 @default.
• W2318373338 hasIssue "Meeting Abstracts 1" @default.
• W2318373338 hasLocation W23183733381 @default.
• W2318373338 hasOpenAccess W2318373338 @default.
• W2318373338 hasPrimaryLocation W23183733381 @default.
• W2318373338 hasRelatedWork W1779352265 @default.
• W2318373338 hasRelatedWork W193065223 @default.
• W2318373338 hasRelatedWork W1969567395 @default.
• W2318373338 hasRelatedWork W2004839802 @default.
• W2318373338 hasRelatedWork W2029259703 @default.
• W2318373338 hasRelatedWork W2076863510 @default.
• W2318373338 hasRelatedWork W207924865 @default.
• W2318373338 hasRelatedWork W2086815472 @default.
• W2318373338 hasRelatedWork W2266546919 @default.
• W2318373338 hasRelatedWork W2303917887 @default.
• W2318373338 hasRelatedWork W2315357470 @default.
• W2318373338 hasRelatedWork W2316958950 @default.
• W2318373338 hasRelatedWork W2317419576 @default.
• W2318373338 hasRelatedWork W2330784951 @default.
• W2318373338 hasRelatedWork W2331764873 @default.
• W2318373338 hasRelatedWork W2415276118 @default.
• W2318373338 hasRelatedWork W2738895577 @default.
• W2318373338 hasRelatedWork W2757284223 @default.
• W2318373338 hasRelatedWork W2773151400 @default.
• W2318373338 hasRelatedWork W2774277489 @default.
• W2318373338 hasVolume "78" @default.
• W2318373338 isParatext "false" @default.
• W2318373338 isRetracted "false" @default.
• W2318373338 magId "2318373338" @default.
• W2318373338 workType "article" @default.